Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst

Bank of America Securities connected with Intuitive Surgical Inc (NASDAQ:ISRG) on reprocessing “noise” in the market.

Analyst Travis Steed highlighted that reprocessing is not new to Intuitive, even though it might seem like new news to some investors.

What Happened: For the unversed, in March this year, Restore Robotics received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for remanufacturing Intuitive Surgical’s Da Vinci Xi Monopolar Scissors as of March 11, 2025, through its subsidiary Iconocare Health.

In a statement, Restore Robotics said it is offering hospitals and surgery centers a cost-effective and sustainable alternative to purchasing instruments from the original manufacturer.

Also Read: Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty

In May, Restore Robotics announced that Dr. Eugene Dickens at Hillcrest Medical Center in Tulsa, Oklahoma, conducted the first in-human use of a remanufactured da Vinci  Xi robotic instrument on a patient using the newest model robotic surgical system, the da Vinci 5.

In addition, Panama City Surgery Center performed the first in-human use on a da Vinci Xi, which is the workhorse of the da Vinci robotics surgical ...